BridgeBio Pharma, Inc. BBIO
BridgeBio Pharma, Inc. is a commercial-stage, multi-product biopharmaceutical company organized around a portfolio operating model to discover, develop, and deliver medicines for patients with genetic diseases. 10-K, Item 1
- Headquarters
- Palo Alto, CA
- CEO
- Neil Kumar
- Next results
- around Jan 11, 2027
BBIO among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
20 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 24, 2026 against Feb 20, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
9 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 8 checks found nothing to note
-
Receivables growing faster than revenueReceivables +2853.1% ($4.7M to $139.4M) vs revenue +126.3% ($221.9M to $502.1M), +2726.8 pts apart
-
Cash from operations −$445.9M vs net income −$732.9M (FY ending Dec 31, 2025)
7 more checks with nothing to note
-
Same auditor in both 10-Ks: Deloitte & Touche LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
20 paragraphs in Risk Factors that were not in the 10-K filed Feb 20, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at containing or lowering the cost of healthcare. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or…
-
Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
Federal legislative and regulatory efforts to implement reference pricing or most-favored-nation pricing models could impact our product revenues and materially harm our business. On May 12, 2025, the current administration issued an executive order calling on pharmaceutical manufacturers to voluntarily reduce the prices of medicines in…
-
Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
On February 3, 2026, Congress passed the Consolidated Appropriations Act of 2026. The RARE Act codified the FDA’s longstanding regulatory interpretation that orphan drug exclusivity applies only to the specific approved use or indication of a drug or biological product, rather than to all uses within a designated rare disease or condition.
-
Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
The Consolidated Appropriations Act of 2026 reauthorized the FDA’s authority to award priority review vouchers to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029. Under current law, after September 30, 2029, the FDA may not award any rare pediatric disease priority review vouchers, although…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $77.6M | $9.3M | $221.9M | $502.1M |
| Net income | −$481.2M | −$643.2M | −$535.8M | −$724.9M |
| Operating cash flow | −$419.5M | −$527.7M | −$520.7M | −$445.9M |
| Free cash flow | −$424.3M | −$529.0M | −$521.7M | −$447.0M |
Revenue, FY2019 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$502.1M ▲ 126.3% in FY2025−$724.9M in FY2025−$447.0M in FY2025
Recent filings
4 filings in the last 30 days · SEC EDGAR
-
SEC letterNov 13, 2026SEC asked 36 questions about Form S-1 letters Mar 14, 2019 to Jun 25, 2019 · Results discussion (MD&A), Legal and contingencies, Critical estimates · no closing letter yet
-
Planned saleOct 29, 2026Charles Homcy (Chairman of Pharmaceuticals and Lead Director on our Board of Directors) adopted a 10b5-1 trading plan reported in the 10-Q, up to 120,000 shares, runs to Sep 4, 2027
-
8-KOct 29, 2026Quarterly results 8-K item 2.02
-
10-QOct 29, 2026Quarterly report (10-Q) period ended Sep 30, 2026
About the company
BridgeBio Pharma, Inc., Palo Alto, CA · from the 10-K filed Feb 24, 2026
BridgeBio Pharma, Inc. is a commercial-stage, multi-product biopharmaceutical company organized around a portfolio operating model to discover, develop, and deliver medicines for patients with genetic diseases. We seek to translate advances in genetic science into therapies for patient populations with significant unmet medical needs. Since our founding 10 years ago, we have advanced multiple programs from discovery through regulatory approval and commercialization. To date, more than 8,500 patients have been treated with our approved medicines, and we have obtained U.S. Food and Drug Administration (the “FDA”) approval for three products.
- Headquarters
- Palo Alto, CA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Oct 29, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Feb 24, 2026 (open at SEC), compared with the 10-K filed Feb 20, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BBIO/export.csv") into a cell.